
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs is a clinical-stage biotechnology company with a positive outlook, as they have a strong pipeline including GEO-MVA, GEO-CM04S1, and Gedeptin for poxviruses and solid tumor cancers. Despite a recent reverse stock split, the potential of Gedeptin in combination with immune checkpoint inhibitors and the differentiated multi-antigen approach of GEO-CM04S1 position Geovax Labs for future value inflection points. However, there is a heightened probability of dilution risk as the company continues to fund clinical development and manufacturing readiness with a constrained balance sheet.
Bears say
Geovax Labs is facing a constrained near-term outlook due to limited catalysts and tightening capital resources, prompting a downgrade from Buy to Hold. Although the company has a potentially differentiated role in the market with its GEO-MVA vaccine candidate for mpox, smallpox, and other poxviruses, the realization of its value will not be seen until a planned Phase 3 immunobridging trial in 2026 and data in 2027. In addition, the company's previous COVID vaccine effort has not translated into sustainable commercial success. As a result, the financial analyst has a negative outlook on Geovax Labs' stock due to the elevated risk of execution and potential dilutive capital raises.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares